
Opinion|Videos|April 11, 2025
Advancing Early Detection: Autoimmune Screening in Type 1 Diabetes
A panelist discusses how autoimmune screening through detection of diabetes-specific autoantibodies serves as a critical tool for identifying pre-symptomatic type 1 diabetes (T1D), enabling earlier intervention before significant beta cell loss occurs and potentially changing the disease trajectory through timely management strategies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What role does autoimmune screening play in identifying and diagnosing patients with T1D earlier?
- In what patients do you recommend screening for autoantibodies?
- Do you think autoimmune screening initiatives will gain momentum in the next few years?
- How can health care systems and payers improve early screening and diagnosis to better preserve beta cell function?
Advertisement
Related to this article

Heidi Overton ran into opposition from Republican senators concerned about her role in setting White House vaccine policy.

Takeda’s Orzeyful, the first orexin agonist for narcolepsy type 1, is now available in the U.S. at a whole acquisition list price of $16,500 per 60-tablet bottle.

The FDA approved Cosentyx for polymyalgia rheumatica after 40.5% of trial patients reached sustained remission at week 52 vs. 20.5% on placebo.

SBE303, a Nectin-4 ADC for previously treated bladder cancer, is in phase 1 as the company advances SB27, its proposed Keytruda biosimilar.

NeosRx CEO Jeff Dunn, Pharm.D., MBA, explains how 340B claims can disadvantage PBMs because of loss of rebates..

A CMS rule moving insulin pumps and CGMs into Medicare bidding by 2028 has drawn a coalition letter and a Senate bill seeking delay.

Patients facing higher out-of-pocket costs predicted procedures would hurt more than procedures with no copay, according to the results of a recent Carnegie Mellon study.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
From Keytruda biosimilar to novel ADC: Samsung Bioepis’ 2-track oncology strategy
2
Takeda launches Orzeyful, first orexin agonist for narcolepsy type 1
3
Quick Q&A: Jeff Dunn, Pharm.D., MBA, on 340B discounts and PBM rebates
4
FDA approves Cosentyx as first anti-IL-17 biologic for polymyalgia rheumatica
5


